JP2024540108A5 - - Google Patents
Info
- Publication number
- JP2024540108A5 JP2024540108A5 JP2024525411A JP2024525411A JP2024540108A5 JP 2024540108 A5 JP2024540108 A5 JP 2024540108A5 JP 2024525411 A JP2024525411 A JP 2024525411A JP 2024525411 A JP2024525411 A JP 2024525411A JP 2024540108 A5 JP2024540108 A5 JP 2024540108A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- compound
- independently
- lipid nanoparticles
- mol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21205904.2 | 2021-11-02 | ||
| EP21205904 | 2021-11-02 | ||
| EP22179399 | 2022-06-16 | ||
| EP22179399.5 | 2022-06-16 | ||
| PCT/EP2022/080581 WO2023078950A1 (en) | 2021-11-02 | 2022-11-02 | Lipid nanoparticles for oligonucleotide delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540108A JP2024540108A (ja) | 2024-10-31 |
| JP2024540108A5 true JP2024540108A5 (cg-RX-API-DMAC7.html) | 2025-10-31 |
Family
ID=84364268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525411A Pending JP2024540108A (ja) | 2021-11-02 | 2022-11-02 | オリゴヌクレオチド送達のための脂質ナノ粒子 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250236599A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4426270B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024540108A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240099377A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022381463A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3236653A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK4426270T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3042660T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI4426270T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312432B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005109A (cg-RX-API-DMAC7.html) |
| PL (1) | PL4426270T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023078950A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202403360B (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12678515B2 (en) | 2015-12-30 | 2026-07-14 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| CA3116576A1 (en) | 2018-10-18 | 2020-04-23 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| JP2025538515A (ja) * | 2022-11-25 | 2025-11-28 | 艾斯拓康医薬科技(北京)有限公司 | イオン化脂質及びその応用 |
| JP2025534494A (ja) * | 2022-12-23 | 2025-10-15 | グリーン・クロス・コーポレイション | イオン化可能な脂質及びその使用 |
| CN119219539A (zh) * | 2023-06-29 | 2024-12-31 | 艾斯拓康医药科技(北京)有限公司 | 可离子化脂质及其应用 |
| WO2025088152A1 (en) | 2023-10-27 | 2025-05-01 | Ziphius Nv | MODIFIED 5'UTRs |
| US12599560B2 (en) | 2023-11-02 | 2026-04-14 | Longuide Biopharma Corporation | Lipids and lipid nanoparticle formulations |
| AU2024381228A1 (en) | 2023-11-13 | 2026-05-28 | Ziphius Nv | MODIFIED ALPHAVIRAL nsP3 |
| WO2025128696A1 (en) * | 2023-12-12 | 2025-06-19 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| WO2025255534A1 (en) * | 2024-06-07 | 2025-12-11 | Innovac Therapeutics Hk Limited | Diol-based novel ionizable lipids and their uses thereof |
| WO2026112559A1 (en) * | 2024-11-25 | 2026-05-28 | Genzyme Corporation | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
| WO2026117525A1 (en) * | 2024-11-26 | 2026-06-04 | Flagship Pioneering Innovations Vii, Llc | Ionizable lipidoid compositions and therapeutic uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| PT1751289E (pt) | 2004-05-18 | 2009-03-31 | Alphavax Inc | Vectores de alfavirais derivados da tc-83, partículas e métodos |
| US7332322B2 (en) | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
| WO2014028487A1 (en) * | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
| CA2953341C (en) * | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| KR20190093816A (ko) * | 2016-10-26 | 2019-08-26 | 큐어백 아게 | 지질 나노입자 mRNA 백신 |
| EP3638678B1 (en) * | 2017-06-14 | 2025-12-03 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
-
2022
- 2022-11-02 MX MX2024005109A patent/MX2024005109A/es unknown
- 2022-11-02 AU AU2022381463A patent/AU2022381463A1/en active Pending
- 2022-11-02 WO PCT/EP2022/080581 patent/WO2023078950A1/en not_active Ceased
- 2022-11-02 ES ES22813505T patent/ES3042660T3/es active Active
- 2022-11-02 CA CA3236653A patent/CA3236653A1/en active Pending
- 2022-11-02 JP JP2024525411A patent/JP2024540108A/ja active Pending
- 2022-11-02 KR KR1020247018058A patent/KR20240099377A/ko active Pending
- 2022-11-02 PL PL22813505.9T patent/PL4426270T3/pl unknown
- 2022-11-02 EP EP22813505.9A patent/EP4426270B1/en active Active
- 2022-11-02 IL IL312432A patent/IL312432B2/en unknown
- 2022-11-02 EP EP25189933.2A patent/EP4613741A3/en not_active Withdrawn
- 2022-11-02 FI FIEP22813505.9T patent/FI4426270T3/fi active
- 2022-11-02 US US18/705,479 patent/US20250236599A1/en active Pending
- 2022-11-02 DK DK22813505.9T patent/DK4426270T3/da active
-
2024
- 2024-04-30 ZA ZA2024/03360A patent/ZA202403360B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024540101A5 (cg-RX-API-DMAC7.html) | ||
| FI4426270T3 (fi) | Lipidi-nanopartikkelit oligonukleotidien kuljetusta varten | |
| JP2025041652A5 (cg-RX-API-DMAC7.html) | ||
| JP6592458B2 (ja) | カチオン性脂質 | |
| US7709449B2 (en) | Nucleic acid-based compounds and methods of use thereof | |
| ES2924806T3 (es) | Análogos de 4'-fosfato y oligonucleótidos que comprenden el mismo | |
| JP2021535226A5 (cg-RX-API-DMAC7.html) | ||
| JP2021535227A5 (cg-RX-API-DMAC7.html) | ||
| WO2007095976A2 (de) | Adjuvanz in form einer lipid-modifizierten nukleinsäure | |
| JP2019525918A5 (cg-RX-API-DMAC7.html) | ||
| EA022757B1 (ru) | МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК | |
| JP2023534206A5 (cg-RX-API-DMAC7.html) | ||
| JP2015521626A (ja) | ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤 | |
| JP2022546557A5 (cg-RX-API-DMAC7.html) | ||
| JP2022536495A5 (cg-RX-API-DMAC7.html) | ||
| JP2020512293A (ja) | インフュージョンリアクションを改善するための方法 | |
| JP2019527549A5 (cg-RX-API-DMAC7.html) | ||
| EP3400008A2 (en) | Therapeutic compositions and methods for treating hepatitis b | |
| WO2024019770A1 (en) | Methods of making ionizable lipids and lipid nanoparticles for mrna delivery | |
| CN118105357B (zh) | 一种鞘内递送制剂及其用途 | |
| JP2025038098A (ja) | 筋ジストロフィーに対するエクソンスキッピングオリゴマー | |
| CN120359208A (zh) | 可电离脂质及其用途 | |
| JP7658900B2 (ja) | 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート | |
| JP2018518167A5 (cg-RX-API-DMAC7.html) | ||
| WO2023176822A1 (ja) | 化合物および脂質組成物 |